+1-800-267-5763
October 2022
Canadian Ophthalmological Society (COS) Joint Position Statement on Biosimilar Drugs
Biosimilar biologic drugs (biosimilars*) were introduced in the Canadian market in 2009. The first ophthalmic biosimilar for intravitreal injection is expected to be launched in Canada in the late fall of 2022. With this launch, it is expected that use of biosimilars across Canada will rapidly increase.